Apheris

Cover Block

Name	Apheris
Tagline	Federated infrastructure for training AI on sensitive pharma data without centralizing it. [apheris.com]
Headquarters	Berlin, Germany
Founded	2019 [TechCrunch, Jan 2025]
Stage	Series A
Business Model	SaaS
Industry	Deeptech
Technology	AI / Machine Learning
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Series A (total disclosed ~$20,800,000) [Crunchbase, Retrieved 2026]

Links

• Website: https://www.apheris.com/
• LinkedIn: https://www.linkedin.com/company/apheris/
• X / Twitter: https://x.com/apheris_AI

The Short Version

Apheris provides the technical and governance infrastructure to train AI models across the highly sensitive, proprietary datasets of pharmaceutical companies without requiring that data to leave its original secure environment. This federated approach addresses a critical bottleneck in drug discovery, where valuable data is often siloed by regulation and competition [TechCrunch, Jan 2025]. The founding story is rooted in this problem, with CEO Robin Röhm having previously lost customers at a prior startup due to the inability to centralize data for analysis under regulatory constraints [apheris.com].

Its core product, the Apheris Gateway, is an end-to-end solution that enables collaborative machine learning, allowing competing or cooperating entities to build better predictive models while maintaining strict control over their data assets [apheris.com]. The founding team combines a deep understanding of the life sciences domain with technical execution: Röhm's background spans medicine, philosophy, and mathematics, while CTO Michael Höh holds a PhD in physics and computer science and previously built AI applications at BCG [apheris.com].

Financially, the company is backed by a disclosed $20.8 million Series A round closed in January 2025, with investors including OTB Ventures and eCAPITAL [Crunchbase, Retrieved 2026]. Over the next 12-18 months, the key indicator to watch will be the expansion of its named, multi-party data networks like the ADMET Network, which includes founding members Lundbeck, Orion Pharma, Recursion, and Servier [GEN].

Data Accuracy: GREEN -- Core company claims and funding details corroborated by primary sources and multiple press reports.

Taxonomy Snapshot

Axis	Classification
Stage	Series A
Business Model	SaaS
Industry / Vertical	Deeptech
Technology Type	AI / Machine Learning
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Series A (total disclosed ~$20,800,000)

The Company in Brief

Apheris was founded in Berlin in 2019 by Robin Röhm and Michael Höh [TechCrunch, Jan 2025]. The founding narrative stems from Röhm's prior startup experience, where regulatory constraints prevented the centralization of data necessary for collaborative AI work [apheris.com]. This encounter with the data bottleneck in regulated industries became the catalyst for Apheris, which was built to enable model training across distributed, sensitive datasets without moving them.

The company's early development culminated in a public platform launch in September 2021 [apheris.com]. A significant operational milestone followed in January 2025 with the close of a $20.8 million Series A financing round [Crunchbase, Retrieved 2026] [eCAPITAL, Retrieved 2026].

Data Accuracy: GREEN -- Founding date and team confirmed by TechCrunch and company website; funding round corroborated by multiple independent sources.

What They Have Built

Apheris sells a federated computing infrastructure. The core product, the Apheris Gateway, is an end-to-end platform designed to let life sciences organizations train machine learning models on distributed, sensitive datasets without moving the data to a central location [apheris.com]. The company enables "life science data networks," where participants can collaborate across organizational boundaries while maintaining strict governance, security, and privacy controls [apheris.com].

The platform's functionality includes secure local use for benchmarking, controlled customization of shared models, and access to models trained across aggregated industry data [apheris.com]. Technical components include a Command Line Interface (CLI) for managing datasets, compute specifications, and jobs, as well as an Apheris Statistics package for privacy-sensitive federated statistical analysis [apheris.com]. The technology stack integrates with existing cloud infrastructure; the company is an AWS Technology Partner and has demonstrated federated learning workflows on NVIDIA DGX Cloud [Amazon Web Services] [apheris.com].

Public deployments include the ADMET Network, a federated initiative for collaborative ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) model training where founding pharmaceutical members can fine-tune a base model within their own secure environments [GEN Edge]. Apheris also powers a separate AI Structural Biology (AISB) Network and has announced a collaboration to fine-tune the OpenFold3 protein prediction model using proprietary pharma data [apheris.com].

Data Accuracy: GREEN -- Product claims and technical details are confirmed by the company's own website and blog, with network deployments corroborated by third-party press.

Market Size and Demand

The market for federated computing in drug discovery is defined by the tension between the value of proprietary data for training AI models and the legal and competitive barriers to sharing it.

The broader AI in drug discovery and development market was valued at $1.2 billion in 2023 and is projected to grow at a compound annual growth rate of 29.1% through 2030 [Grand View Research, 2024]. Separately, the global federated learning solutions market was estimated at $127 million in 2022 and is forecast to reach $210 million by 2028 [MarketsandMarkets, 2023].

Demand is propelled by the escalating cost and complexity of drug R&D and the tightening global regulatory environment for data privacy and sovereignty, which makes traditional data centralization increasingly impractical [GEN, 2024]. The company's materials cite the formation of industry-specific data networks, like the ADMET Network, as evidence of a shift towards collaborative but controlled data utilization [apheris.com].

Metric	Value
AI in Drug Discovery (2023)	$1,200M
Federated Learning Solutions (2022)	$127M

Data Accuracy: YELLOW -- Market sizing figures are drawn from third-party analyst reports and provide an analogous, not direct, view of the target niche.

Who Else Is Fighting for This

Apheris competes in a nascent market for federated learning infrastructure, with a vertical focus on the data governance and collaborative workflows of pharmaceutical R&D.

Company	Positioning	Stage / Funding	Notable Differentiator
Apheris	Federated infrastructure for AI training on sensitive pharma data.	Series A (~$20.8M total).	Vertical focus on life sciences; operates federated data networks.
Rhino Health	Federated learning platform for healthcare data.	Venture stage.	Strong focus on medical imaging and clinical trial data.
Owkin	Federated learning for biomedical research and drug discovery.	Series B+.	Owns the Substra open-source framework; established pharma partnerships.
NVIDIA	Open-source federated learning framework (NVIDIA FLARE).	Public company.	Deep integration with NVIDIA's AI stack and hardware.
Sherpa.ai	Enterprise federated learning and privacy-preserving AI platform.	Venture stage.	Broader horizontal enterprise focus.

Apheris's current edge is its execution on the network model, actively building and operating multi-party federated data networks [GEN]. This moves the company beyond selling tooling to orchestrating industry consortia. The company's partnership with Amazon Web Services as a technology partner for Amazon Bio Discovery provides a credible channel [Amazon Web Services], [bio-itworld.com, 2026].

Data Accuracy: YELLOW -- Competitor positioning inferred from category descriptions; specific funding and stage details for competitors are not fully corroborated by independent public sources.

Opportunity

Apheris is positioned to capture the economic upside of a pharmaceutical industry forced to collaborate on AI without surrendering proprietary data. The headline opportunity is to become the default federated computing infrastructure for the global life sciences industry. The formation of multi-party industry consortia, such as the ADMET Network with members Lundbeck, Orion Pharma, Recursion, and Servier, demonstrates that competing pharmaceutical firms are willing to adopt a shared, neutral platform [GEN Edge].

Scenario	What happens	Catalyst	Why it's plausible
Platform Standardization	Apheris Gateway becomes the mandated technical layer for all new industry data consortia.	A major regulatory body or industry group endorses the platform.	The company is an AWS technology partner and provides AI models for the Amazon Bio Discovery initiative.
Vertical Expansion into Healthcare	The infrastructure is adapted for hospital systems to collaborate on diagnostic AI models.	A partnership with a large hospital network to launch a federated research network.	The platform handles medical imaging data types like DICOM.
Embedded Infrastructure	Apheris's federated orchestration layer is white-labeled or embedded within cloud service offerings.	A formal co-sell or go-to-market partnership with a cloud provider.	Technical integration work is evidenced by collaborations on federated learning with NVIDIA DGX Cloud.

Data Accuracy: YELLOW -- Core product claims and the ADMET Network launch are confirmed by company and press sources. Growth scenarios are extrapolations based on cited technical capabilities.

Sources

1. [TechCrunch, Jan 2025] Apheris rethinks the AI data bottleneck in life science with federated computing | https://techcrunch.com/2025/01/02/apheris-rethings-the-ai-data-bottleneck-in-life-science-with-federated-computing/
2. [apheris.com] Superior drug discovery models | https://www.apheris.com/
3. [apheris.com] About Apheris | https://www.apheris.com/company
4. [apheris.com] Build & join life science data networks | https://www.apheris.com/product
5. [apheris.com] Advancing protein prediction with Federated Learning on NVIDIA DGX Cloud | https://www.apheris.com/resources/blog/advancing-protein-prediction-with-federated-learning-on-nvidia-dgx-cloud
6. [apheris.com] AlQuraishi lab’s OpenFold3 to Be Fine-Tuned with Pharma Industry Data in a Secure AI Collaboration Powered by Apheris | https://www.apheris.com/resources/blog/alquraishi-lab-s-openfold3-to-be-fine-tuned-with-pharma-industry-data-in-a-secure
7. [Crunchbase, Retrieved 2026] Apheris Company Profile | https://www.crunchbase.com/organization/apheris
8. [eCAPITAL, Retrieved 2026] eCAPITAL invests in Apheris | https://www.ecapital.vc/en/news/ecapital-invests-in-apheris/
9. [GEN Edge] ADMET Predictions Get AI Boost, Federated Data Network Unites Pharma | https://www.genengnews.com/gen-edge/admet-predictions-get-ai-boost-federated-data-network-unites-pharma/
10. [Amazon Web Services] AWS Partner: Apheris | https://aws.amazon.com/partners/find/partnerdetails/?id=0010h00002FJq4FAAT
11. [bio-itworld.com, 2026] Amazon Bio Discovery Partners | https://www.bio-itworld.com/news/2026/01/15/amazon-bio-discovery-partners
12. [Grand View Research, 2024] AI in Drug Discovery Market Size Report, 2024-2030 | https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-in-drug-discovery-market
13. [MarketsandMarkets, 2023] Federated Learning Solutions Market | https://www.marketsandmarkets.com/Market-Reports/federated-learning-market-166699074.html